AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01399684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-Fluorouracil
Description: Participants will receive 5-fluorouracil 400 milligrams per squared meter (mg/m\^2) intravenous (IV) bolus and then 2400 mg/m\^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
Study NCT01399684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will be administered bevacizumab at a dose of 5 milligrams per kilogram (mg/kg) every 14 days until disease progression or unacceptable toxicity, for a maximum of 52 cycles, whichever occurs first.
Study NCT01399684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: Participants will be administered bevacizumab at a dose of 5 milligrams per kilogram (mg/kg) every 14 days until disease progression or unacceptable toxicity, for a maximum of 52 cycles, whichever occurs first.
Study NCT01399684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: Participants will receive folinic acid 400 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
Study NCT01399684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folinic acid
Description: Participants will receive folinic acid 400 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
Study NCT01399684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEGF0444A
Description: Participants will be administered MEGF0444A at a fixed dose of 400 milligrams (mg) IV on Day 1 of Cycle 1, followed by subsequent doses of 400 mg every 14 days until disease progression or unacceptable toxicity, for a maximum of 52 cycles, whichever occurs first.
Study NCT01399684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 90 minutes on Day 1 of every cycle for a maximum of 8 cycles.
Study NCT01399684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 90 minutes on Day 1 of every cycle for a maximum of 8 cycles.
Study NCT01399684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered MEGF0444A matching placebo every 14 days until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
Study NCT02271737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training HC/VHSG, Health Education, and Supportive Supervision
Description: 1. Improve infection control Practice at health centers; 2) improve knowledge on newborn danger signs among HC staff, VHSG, and the mothers; 3) improve care coordination between community and health facilities, e.g. improve referral of sick newborns
Study NCT02790047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A non-re-breathing face mask with conical-PEP device
Description: Participant will use a non-re-breathing face mask with conical-PEP device during an interval endurance spot marching exercise.
Study NCT02790047 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A home-base exercise program
Description: Duration of the program is 8 weeks A frequency of exercise session is 3 to 5 sessions per week A content of each exercise session includes~1. Stretching exercise (shoulder, trunk and leg muscles) to warm up for 5 to 10 minutes~2. Interval endurance exercise using a spot marching movement for 30 to 40 minutes. In each phase of spot marching exercise, patients will perform the exercise from 0 to 3 or 4 score of 10 score of a modified dyspnea Borg scale, they will record exercise the exercise duration time. Then, they will be required to rest until a modified dyspnea Borg scale \< 1 score. Next, they will perform the next interval of spot marching exercise with the same protocol.~3. Stretching exercise (shoulder, trunk and leg muscles) to cool down for 5 to 10 minutes
Study NCT02790047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A home-base exercise program
Description: Duration of the program is 8 weeks A frequency of exercise session is 3 to 5 sessions per week A content of each exercise session includes~1. Stretching exercise (shoulder, trunk and leg muscles) to warm up for 5 to 10 minutes~2. Interval endurance exercise using a spot marching movement for 30 to 40 minutes. In each phase of spot marching exercise, patients will perform the exercise from 0 to 3 or 4 score of 10 score of a modified dyspnea Borg scale, they will record exercise the exercise duration time. Then, they will be required to rest until a modified dyspnea Borg scale \< 1 score. Next, they will perform the next interval of spot marching exercise with the same protocol.~3. Stretching exercise (shoulder, trunk and leg muscles) to cool down for 5 to 10 minutes
Study NCT02790047 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Health education include~1. Knowledge of COPD disease~2. Smoking status and smoking cessation~3. Medication correctly~4. Self dyspnea management~5. Basic nutrition for COPD
Study NCT00544115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Study NCT02790047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education
Description: Health education include~1. Knowledge of COPD disease~2. Smoking status and smoking cessation~3. Medication correctly~4. Self dyspnea management~5. Basic nutrition for COPD
Study NCT02790047 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ฺBreathing strategies for self secretion clearance
Description: Using a modified active cycle breathing technique (mACBT) include~1. Control breathing~2. Pursed lip breathing (PLB)~3. Slow inhale with sustain thoracic expansion for 3 sec and exhale with PLB technique~4. Force expiratory technique (FET) with low to medium lung volume~5. Huffing or coughing
Study NCT02790047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ฺBreathing strategies for self secretion clearance
Description: Using a modified active cycle breathing technique (mACBT) include~1. Control breathing~2. Pursed lip breathing (PLB)~3. Slow inhale with sustain thoracic expansion for 3 sec and exhale with PLB technique~4. Force expiratory technique (FET) with low to medium lung volume~5. Huffing or coughing
Study NCT00544115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus
Study NCT02790047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The medication following the COPD GOLD guidelines (2015)
Description: Patients will receive medications following the COPD GOLD guidelines (2015). The medication names were listed below~1. Bata 2 agonist (short acting); Salbutamol (oral or inhaler), Terbutaline (oral)~2. Bata 2 agonist (long acting); Bambuterol (oral), Procaterol (oral), Salmeterol (inhaler), Formoterol (inhaler)~3. Xanthine derivative (sustained release theophylline)~4. Anticholinergic; Tiotropium(inhaler), Ipratropium bromide (inhaler)~5. Corticosteroids; Beclomethasone (inhaler), Budesonide(inhaler), Fluticasone(inhaler)~6. Combined anticholinergic+ Beta 2-agonist; Ipratropium+fenoterol (inhaler), Ipratropium+salbutamol (inhaler)~7. Combined Beta 2-agonist+ corticosteroids; Formoterol+ Budesonide(inhaler), Salmeterol+ Fluticasone(inhaler)
Study NCT00544115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Study NCT00544115 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: allogeneic hematopoietic stem cell transplantation
Study NCT00544115 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral blood stem cell transplantation
Study NCT00544115 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: total-body irradiation
Study NCT00695292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: irinotecan 60 mg/m2 intravenously (IV) on Days 1, 8, and 15
Study NCT00695292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC=4 on Day 1
Study NCT00695292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: sunitinib 25 mg orally (PO) daily after initial chemotherapy
Study NCT02759172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Planning Intervention
Description: Brown and Stanley's Safety Planning Intervention (SPI) is a brief, adjunctive intervention designed to reduce subsequent suicidal behavior in high-risk populations. The core element of SPI is the collaborative development of the Safety Plan, which is a prioritized written list of coping strategies and supports that individuals can use during or preceding suicidal crises. In this study, safety planning will occur during pretrial jail detention, with telephone follow-up in the community to conduct risk assessment, review the Safety Plan, problem-solve obstacles to treatment, and assist with linkage to services.
Study NCT01033032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amrubicin
Description: Phase I: dose-escalating portion with the starting dose of amrubicin at 90mg/m\^2 IV q21 days. Dose escalations are as follows:~DL2 - 100mg/m\^2; DL3 - 110mg/m\^2; and DL4 - 120mg/m\^2. All cycles are q21 days~Phase II: Amrubicin will be administered at the maximum tolerated dose established in Phase I by IV every 21 days
Study NCT04172259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin liposome
Description: PLD
Study NCT04172259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: CTX
Study NCT04172259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: CTX
Study NCT04172259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: H
Study NCT04172259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: H
Study NCT04172259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: DOC
Study NCT04172259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: DOC
Study NCT04172259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: EPI
Study NCT04172259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: P
Study NCT04172259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: P
Study NCT04172259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: paclitaxel (PTX) 175 mg/m2 every 3 weeks or paclitaxel (PTX) 80 mg/m2 every week
Study NCT04172259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel-albumin
Description: albumin-bound paclitaxel 260 mg/m2 or albumin-bound paclitaxel 100 mg/m2 every week
Study NCT04172259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel-albumin
Description: albumin-bound paclitaxel 260 mg/m2 or albumin-bound paclitaxel 100 mg/m2 every week
Study NCT04030390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Fatigue
Description: Maximal cycling effort for 30s (Wingate modified)
Study NCT04030390 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: time-matched task (sitting on the bike without pedalling)
Study NCT03831360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Hatha yoga for depressed adolescents
Study NCT03831360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group CBT
Description: Group cognitive behavioral therapy for depressed adolescents
Study NCT04693832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5inD
Description: Interactive Mobile Application which is includes five different game (mandala, puzzle, tetris, music, breath exercise)
Study NCT00661609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4877
Description: Intravenous (IV)25mg/weekly
Study NCT03428113 — intervention group
Intervention type: OTHER
Intervention: Bladder Volume Measurement bladder scanner RN
Description: Measure Urine Volume with Bladder Scanner by RN
Study NCT03428113 — intervention group
Intervention type: OTHER
Intervention: Bladder Volume Measurement Ultrasound APRN
Description: Measure Urine Volume with Point of Care Ultrasound by APRN
Study NCT03428113 — intervention group
Intervention type: OTHER
Intervention: Bladder Volume Measurement bladder scanner APRN
Description: Measure Urine Volume with Bladder Scanner by APRN
Study NCT03428113 — intervention group
Intervention type: OTHER
Intervention: Bladder Volume Measurement Ultrasound MD
Description: Measure Urine Volume with Point of Care Ultrasound by MD
Study NCT03428113 — intervention group
Intervention type: OTHER
Intervention: Intermittent Straight Catheterization
Description: Measure Urine Volume with Intermittent Straight Catheterization
Study NCT03008863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Study NCT01180751 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: [18F]-Fluorodeoxyglucose
Description: With each Positron Emission Tomography/Computed Tomography (PET/CT)scan an intravenous administration of radioactive glucose (FDG)is given. This is a weight dependent dosage.
Study NCT00526812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 744
Description: Aqueous solution added to 10%D/W and infused over 2 hours on three consecutive days. 5 mg vials contain 1 mg/ml.
Study NCT00526812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 744 injection
Description: Aqueous solution in 1mg/ml. Doses are escalated. Drug is infused intravenously over 2 hours one day a week for four consecutive weeks.
Study NCT01566695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azacitidine
Description: 300 mg daily, days 1 to 21 of each 28-day treatment cycle
Study NCT01566695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically matching placebo tablets on day 1 to 21 of each 28-day treatment cycle.
Study NCT01566695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportiv Care (BSC)
Description: BSC included and was not limited to packed RBC (packed red blood cell \[pRBC\] and whole blood), platelet transfusions (single donor or pooled donor), antibiotic, antiviral and/or antifungal therapy, nutritional support, and granulocyte colony stimulating factors (G-CSF) for participants who experienced neutropenic fever/infections.
Study NCT01566695 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportiv Care (BSC)
Description: BSC included and was not limited to packed RBC (packed red blood cell \[pRBC\] and whole blood), platelet transfusions (single donor or pooled donor), antibiotic, antiviral and/or antifungal therapy, nutritional support, and granulocyte colony stimulating factors (G-CSF) for participants who experienced neutropenic fever/infections.
Study NCT04181827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-68284528
Description: Cilta-cel infusion will be administered at a target dose of 0.75 \* 10\^6 CAR-positive viable T cells/kilogram (kg).
Study NCT04181827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide 4 mg will be administered orally.
Study NCT04181827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3 milligram per meter square (mg/m\^2) will be administered subcutaneously (SC).
Study NCT04181827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg/day (10mg/day for participants >75 years of age) (on bortezomib treatment days and the days following bortezomib treatment) will be administered orally in PVd treatment; and orally or intravenous (IV) at 40 mg weekly (20mg weekly for participants >75 years of age) in DPd treatment.
Study NCT04181827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab 1800 mg will be administered SC.
Study NCT00617695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolmitriptan
Description: 5mg nasal spray
Study NCT00617695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02790047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The medication following the COPD GOLD guidelines (2015)
Description: Patients will receive medications following the COPD GOLD guidelines (2015). The medication names were listed below~1. Bata 2 agonist (short acting); Salbutamol (oral or inhaler), Terbutaline (oral)~2. Bata 2 agonist (long acting); Bambuterol (oral), Procaterol (oral), Salmeterol (inhaler), Formoterol (inhaler)~3. Xanthine derivative (sustained release theophylline)~4. Anticholinergic; Tiotropium(inhaler), Ipratropium bromide (inhaler)~5. Corticosteroids; Beclomethasone (inhaler), Budesonide(inhaler), Fluticasone(inhaler)~6. Combined anticholinergic+ Beta 2-agonist; Ipratropium+fenoterol (inhaler), Ipratropium+salbutamol (inhaler)~7. Combined Beta 2-agonist+ corticosteroids; Formoterol+ Budesonide(inhaler), Salmeterol+ Fluticasone(inhaler)
Study NCT00003926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate
Description: Patients receive amifostine intravenous (IV) over 5 minutes beginning 30 minutes prior to melphalan and thiotepa administration on days -5 to -1.~Cohorts of 3-6 patients receive escalating doses of amifostine until the maximum tolerated dose is determined.
Study NCT00003926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Patients receive oral busulfan every 6 hours on days -8 to -6.
Study NCT01397396 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Three times daily inspiratory muscle training (2x30 breaths) at an intensity of >50% Pi,max
Study NCT01397396 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Inspiratory Muscle Training
Description: Three times daily inspiratory muscle training (2x30 breaths) at an intensity of >50% Pi,max
Study NCT01683617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping skills and relaxation training with new technologies
Study NCT00003926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: All patients receive filgrastim (G-CSF) IV for 1 week.
Study NCT00003926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: melphalan intravenous (IV) over 30 minutes on days -5 and -4
Study NCT00003926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: thiotepa intravenous (IV) over 2 hours on days -3 and -2.
Study NCT00003926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation (PBSC)
Description: PBSC are reinfused on day 0
Study NCT02727790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulator
Study NCT02429232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 30mg/tablet once daily
Study NCT02429232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: Linagliptin 5mg/tablet once daily
Study NCT04244708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus temozolomide
Description: undergoing fractionated radiotherapy at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks, for a total dose of 54 Gy, plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
Study NCT04244708 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy plus placebo
Description: undergoing fractionated radiotherapy at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks, for a total dose of 54 Gy, plus placebo
Study NCT01456299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil 1
Description: Remifentanil 1: The R1 group, which received a target effect-site remifentanil concentration of 1 ng/ml.
Study NCT01456299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control group, which received an infusion of normal saline
Study NCT01456299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil 2
Description: Remifentanil 2: The R2group, which received a target effect-site remifentanil concentration of 2 ng/ml.
Study NCT01683617 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional coping skills and relaxation training
Study NCT01633827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Subjects will receive a sugar pill (in combination with room air) during their placebo arm studies
Study NCT01633827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sedative
Description: Subjects will receive eszopiclone (in combination with medical oxygen) during their treatment arm studies
Study NCT01633827 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Room air
Description: Subjects will receive room air (in combination with a sugar pill) during their placebo arm studies